A study in July 2024 by researchers at Mass Eye and Ear in Boston found that people taking semaglutide for type 2 diabetes or weight loss had a higher risk of developing nonarteritic anterior ischemic optic neuropathy, an eye condition that can cause blindness, than people taking medications other than GLP-1 drugs for diabetes or obesity
Our findings indicate these medications may improve long-term health for people with PAD, in addition to managing blood sugar and weight loss. In this study, researchers reviewed the health records for more than 2,000 adults with PAD and type 2 diabetes to explore the potential benefits of GLP-1 RA medications
The fiber content supports the slowed gastric emptying from your GLP-1 medication, preventing the constipation that many patients experience
This repositioning of the host immune system against established tumors represents a crucial dimension of SFNs anticancer activity
L glutathione is a tripeptide molecule composed of three amino acids: cysteine, glycine, and glutamic acid
